|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Acucela Inc. to Present ACU-4429 Phase 1 Data at the 10th International Symposium on Ocular Pharmacology and Therapeutics
11/30/2011 9:11:30 AM
SEATTLE & VIENNA--(BUSINESS WIRE)--Acucela Inc., a Washington State-based clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, today announced that data for ACU-4429, the Company’s novel, small-molecule visual cycle modulator (VCM) for the treatment of dry age-related macular degeneration (dry AMD), will be highlighted at the 10th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Vienna, Austria from December 1-4, 2011. John W. Chandler, M.D., Acucela’s vice president clinical affairs, will present: “Progress in the Development of ACU-4429 for the Treatment of Dry AMD” during the Retina: Dry AMD portion of the ISOPT program on December 1, 2011, at 4:40 p.m. local time.
|
|
|
|
|
|
|
|
|
|
|